In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Shares of Regulus Therapeutics more than doubled after the company agreed to be acquired by Novartis in a deal with an equity value of up to $1.7 billion. The stock was changing hands at $7.78 in ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

Plans for a large new housing estate on a prime Horsham site have moved a step further forward. Developers Lovell ...

Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment ...